에 대한 최신 뉴스 CervoMed (NASDAQ:CRVO) 주식

CervoMed

CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

People, computer, Two,Busy,Professional,Business,People,Working,In,Office,With,Computer.

Exclusives

Trading Ideas

AAPL

ACON

AMZN

AVGO

CRVO

INTC

MLGO

MSFT

MSTR

NVDA

PLTR

PSTV

QBTS

SMCI

TSLA

오늘은 3월에 벤징가 프로에서 가장 많이 검색된 주식을 살펴보려고 한다. 현재 주가 및 연초 대비 수익률은 4월 1일을 기준으로 하며 배당금은 포함되지 않는다.

독점: 3월 벤징가 프로 최다 검색 티커 20개 - 테슬라, 엔비디아, 애플, 앱러빈 순위는?

Wall Street

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

News

Eurozone

Intraday Update

Markets

CMRX

CPIX

QURE

YEXT

미국 주식은 미국 동부 시간 오후 2시에 혼조세를 보였으며, S&amp;P 500 지수는 화요일 약 0.1% 하락했다. 다우 지수는 0.02% 하락한 44,393.25로 거래되었고, 나스닥 지수는 0.03% 상승한 19,743.54로 거래되었다. S&amp;P 500 지수 또한 0.06% 하락하여 6,049.44로 거래되었다.

뉴욕 오후 2시 시황: S&amp;P 500 소폭 하락, 오토존, 부진한 1분기 실적 발표

CervoMed Inc

Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) has outperformed the market over the past 10 years by 13.19% on an annualized basis producing an average annual return of 23.44%. Currently, Ares Management has a market capitalization of $33.73 billion. 
Buying $100 In ARES: If an investor had bought $100 of ARES stock 10 years ago, it would be worth $826.34 today based on a price of $154.38 for ARES at the time of writing.
<h3>Ares Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745969413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARES

Here's How Much $100 Invested In Ares Management 10 Years Ago Would Be Worth Today

Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>) has outperformed the market over the past 5 years by 10.54% on an annualized basis producing an average annual return of 24.89%. Currently, Aflac has a market capitalization of $59.69 billion. 
Buying $1000 In AFL: If an investor had bought $1000 of AFL stock 5 years ago, it would be worth $2,965.59 today based on a price of $109.20 for AFL at the time of writing.
<h3>Aflac's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745968512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Aflac Stock In The Last 5 Years

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 10 years by 3.2% on an annualized basis producing an average annual return of 13.45%. Currently, Caterpillar has a market capitalization of $148.40 billion. 
Buying $1000 In CAT: If an investor had bought $1000 of CAT stock 10 years ago, it would be worth $3,521.19 today based on a price of $307.36 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745967612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Caterpillar 10 Years Ago Would Be Worth This Much Today

S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) has outperformed the market over the past 10 years by 6.45% on an annualized basis producing an average annual return of 16.7%. Currently, S&amp;P Global has a market capitalization of $150.81 billion. 
Buying $100 In SPGI: If an investor had bought $100 of SPGI stock 10 years ago, it would be worth $465.11 today based on a price of $491.76 for SPGI at the time of writing.
<h3>S&amp;P Global's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745966713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPGI

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

In a country wrestling with rising crime rates, viral videos of smash-and-grab robberies, and heated debates about bail reform, <a href="https://www.benzinga.com/25/04/44940401/elon-musk-says-hell-only-spend-day-or-two-per-week-on-government-matters-to-ensure-fraud-does-not-come-roaring-back-ceos-focus-to-shift-to-tesla-beginning-may">Elon Musk</a> says the conversation has gone dangerously off track.
A few months ago, Musk sat down with Tucker Carlson earlier this year to talk about what he sees as one of America's growing blind spots: misplaced empathy.
"What I see is what I call shallow empathy," Musk said. "People have empathy for the criminals but not empathy for the victims of the criminals."
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Musk wasn't talking about hypothetical issues. He pointed to a hard reality: a small slice of society — "a few percent," as he put it — struggle with severe anger problems or "enjoy hurting other people." Without serious consequences, he warned, they don't just stop.
"If you do not incarcerate them," Musk said, "they will hurt other people."
Rather than asking what makes politicians or activists feel good about themselves, Musk argued society needs a <a href="https://www.benzinga.com/general/social-media/25/04/44973207/elon-musks-critics-on-x-see-sudden-drop-in-visibility-raising-questions-about-platforms-free-speech-commitments">harder conversation about the greater good</a>. "I believe one should have deep empathy and ask, what is the greater good for society?" he said. "Is it better to incarcerate violent criminals and prevent them from hurting people, or to let them loose and allow those people to be hurt? I think the latter is much worse."
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Musk's frustration taps into a <a href="https://nypost.com/2024/11/06/us-news/progressive-los-angeles-da-george-gascon-voted-out/">broader national debate</a>. In cities like Los Angeles, efforts to soften criminal sentencing have triggered public backlash. District Attorney George Gascón, criticized for scaling back prosecutions and sentencing enhancements, faced a tough reelection fight against Nathan Hochman, who promised to bring back stricter penalties in the name of protecting victims.&nbsp;
Carlson agreed with Musk, pointing out that modern thinking seems more concerned with showing compassion toward criminals than with protecting victims.
But Musk wasn't finished. He tied the same kind of shallow decision-making to a wider frustration: the suffocation of innovation in America.
Citing endless regulations, ballooning bureaucracy, and the rise of consultants who profit without building anything, Musk compared the situation to an "Atlas Shrugged" scenario, where true creators are buried under a mountain of red tape.
"I build cars, I build rockets, I build satellite internet," Musk said. "I can't put myself in the mindset of someone who wants to do crime. I don't want to hurt people."
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Musk blamed part of the problem on people growing up in "<a href="https://www.benzinga.com/personal-finance/25/04/44598039/elon-musk-says-were-living-in-the-best-time-and-if-you-disagree-you-probably-should-read-a-history-book-when-else-would-you-want-to-be-alive">safe, sheltered environments</a>," unable to grasp the harsh realities of violence because they've never seen it up close. Well-meaning but naive, they design policies with good intentions — but innocent people pay the price.
His message cuts deeper than crime statistics: in a society built on shallow empathy, the real victims aren't just forgotten — they're sacrificed.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
Image: Shutterstock

Personal Finance

Elon Musk Says 'Shallow Empathy' Is Making Society Worse — Asks If It's Better To Jail Criminals or Let Them Keep Hurting Innocent People

ASM International (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ASMIY#OTC">ASMIY</a>) .

Guidance

ASMIY

ASM International Q2 2025 sales to increase +1% to +6% compared to Q1 at constant currencies.

ASM International (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ASMIY#OTC">ASMIY</a>) expects Sales in FY 2025 to grow by a double-digit percentage range of a 10-20% year on year. &nbsp;

ASM International expects Sales in FY 2025 to grow by a double-digit percentage range of a 10-20% year on year.

A space flight that included Katy Perry and Jeff Bezos' fiancée Lauren Sánchez generated plenty of headlines about their short 11-minute flight and the point of the mission, while it made history for having<a href="https://www.benzinga.com/general/space/25/02/44019974/katy-perry-gayle-king-lauren-sanchez-headline-next-blue-origin-space-flight-how-jeff-bezos-fiancee-crew-will-make-history"> all women aboard.</a>
The company behind the space flight is now taking reservations and deposits for the "new generation of astronauts."
What Happened: Perry, Sánchez and several other women were the latest to<a href="https://www.benzinga.com/general/space/25/04/44786258/katy-perry-lauren-sanchez-among-blue-origins-all-women-ns-31-crew-set-to-take-flight-in-west-texas"> take a trip to space</a> aboard the Blue Origin New Shepard, a space flight company founded by Amazon founder Jeff Bezos.
A <a href="https://x.com/blueorigin/status/1916928601485701442">tweet </a>on X is encouraging those interested in seeing Earth "like never before" to book their trip to space on the New Shepard.
"Return to Earth, Forever Changed," the Blue Origin <a href="https://www.blueorigin.com/new-shepard/fly?utm_campaign=NS_sales_fly_social_campaign&amp;utm_source=partner&amp;utm_medium=social+&amp;utm_content=social_ad">website </a>says.
While in the New Shepard, astronauts soar above the Kármán Line and fly at more than three times the speed of sound. The passing of the Kármán line, the internationally recognized boundary of space 62 miles (100 km) above Earth, is unique as rival space flight company Virgin Galactic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) does not take its astronauts to this line.
Blue Origin completed its first human flights in 2021 and has now completed 11 human space flights, including the latest all-women venture.
Among the bigger names to fly to space with Blue Origin along with pop singer Perry include Bezos himself, William Shatner, Michael Strahan and Dude Perfect's Coby Cotton.
You may not be a billionaire like Jeff Bezos, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/04/45029510/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-62">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Blue Origin reservations are open to anyone 18 years or older by filling out some information, including a description of yourself in less than 500 characters.
The one missing detail in the reservation is the total price involved for an unforgettable "Window seat" to space. The reservation form says a $150,000 fully, refundable deposit is collected by Blue Origin after booking a reservation.
This means the space flight with Blue Origin is more than $150,000. Virgin Galactic, which is currently in a pause of taking humans to space, has charged between $200,000 to $450,000 per person for past space flights.
Virgin Galactic is expected to begin taking people to space again in 2026 as long as it passes required tests and its plan stays on track. Previous<a href="https://www.benzinga.com/news/21/07/21945008/spacex-ceo-elon-musk-books-a-flight-with-richard-bransons-virgin-galactic"> reservation holders for flights </a>with Virgin Galactic included Leonardo DiCaprio, Justin Bieber and Elon Musk. 
Virgin Galactic stock is down 51% year-to-date in 2025 and has fallen over 80% in the last year. Blue Origin remains privately held with Bezos as the owner.
While some people and the Wendy's social media account <a href="https://www.today.com/food/trends/wendys-disses-katy-perry-blue-origin-space-flight-rcna201385">criticized </a>the short flight taken by Perry and the other women, many people would probably welcome the chance to experience space, even if for a short while, if it were more affordable.
Of course, those who read Shatner's book that<a href="https://www.benzinga.com/general/entertainment/22/10/29207326/my-trip-to-space-was-supposed-to-be-a-celebration-instead-it-felt-like-a-funeral-william-sh"> included his details</a> on his trip to space might want to skip the trip.
"When I looked in the opposite direction, into space, there was no mystery, no majestic awe to behold, all I saw was death," Shatner said in his book.
Shatner recalled what he saw as a "cold, dark, black emptiness" unlike any blackness you can see on Earth.
Shatner called the trip and views of space "the strongest feelings of grief I have ever encountered."
"My trip to space was supposed to be a celebration; instead, it felt like a funeral."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/space/24/07/39655161/billionaire-wakes-up-to-find-elon-musk-barefoot-in-his-kitchen-we-made-a-pot-of-tea-and-sat-outside">Billionaire Wakes Up To Find Elon Musk Barefoot In His Kitchen: &#8216;We Made A Pot Of Tea And Sat Outside Under The Stars&#8217;</a></li>
</ul>
Photo: The NS-31 crew, via Blue Origin

Entertainment

SPACE

SPCE

Jeff Bezos Wants To Send You To Space After Katy Perry: Here's How Much A Reservation With Blue Origin Costs

Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) has outperformed the market over the past 20 years by 12.98% on an annualized basis producing an average annual return of 21.06%. Currently, Gartner has a market capitalization of $32.41 billion. 
Buying $100 In IT: If an investor had bought $100 of IT stock 20 years ago, it would be worth $4,668.04 today based on a price of $420.59 for IT at the time of writing.
<h3>Gartner's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745965812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Gartner 20 Years Ago Would Be Worth This Much Today

ASM International (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ASMIY#OTC">ASMIY</a>) reported quarterly earnings of $3.62 per share. This is a 7.89 percent decrease over earnings of $3.93 per share from the same period last year. The company reported $671.98 million in sales this quarter. This is a 3.17 percent decrease over sales of $694.00 million the same period last year.

ASM International Q1 Adj. EPS $3.62 Down From $3.93 YoY, Sales $671.98M Down From $694.00M YoY

Enel Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENIC#NYSE">ENIC</a>) reported quarterly earnings of $0.13 per share. This is a 160 percent increase over earnings of $0.05 per share from the same period last year. The company reported $1.10 billion in sales this quarter. This is a 8.55 percent decrease over sales of $1.21 billion the same period last year.

ENIC

Enel Chile Q1 EPS $0.13 Up From $0.05 YoY, Sales $1.10B Down From $1.21B YoY

Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) sees Q2 sales of $175.000 million-$183.000 million vs $181.96 million analyst estimate.

SIMO

Silicon Motion Technology Sees Q2 Sales $175.000M-$183.000M vs $181.96M Est

Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.45 by 33.33 percent. This is a 6.25 percent decrease over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $166.49 million which beat the analyst consensus estimate of $162.69 million by 2.34 percent. This is a 12.05 percent decrease over sales of $189.31 million the same period last year.

Earnings Beats

Silicon Motion Technology Q1 Adj. EPS $0.60 Beats $0.45 Estimate, Sales $166.49M Beat $162.69M Estimate

E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 20 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $152.68 million which missed the analyst consensus estimate of $153.01 million by 0.22 percent. This is a 3.64 percent decrease over sales of $158.45 million the same period last year.

Earnings Misses

ETWO

Correction: E2open Parent Holdings Q4 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $152.68M Miss $153.01M Estimate

IF Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IROQ#NASDAQ">IROQ</a>) reported quarterly earnings of $0.31 per share. This is a 40.91 percent increase over earnings of $0.22 per share from the same period last year. The company reported $6.40 million in sales this quarter. This is a 18.54 percent increase over sales of $5.40 million the same period last year.

IROQ

IF Bancorp Q3 EPS $0.31 Up From $0.22 YoY, Sales $6.40M Up From $5.40M YoY

In the preceding three months, 7 analysts have released ratings for Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $539.14, a high estimate of $625.00, and a low estimate of $442.00. Witnessing a positive shift, the current average has risen by 0.72% from the previous average price target of $535.29.
<img src="https://www.benzinga.com/files/images/story/2025/1745964071_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Ameriprise Finl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$565.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$510.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$520.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$542.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$570.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$625.00</td>
<td>$625.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Underweight</td>
<td>$442.00</td>
<td>$415.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ameriprise Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ameriprise Finl compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Ameriprise Finl's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ameriprise Finl's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AMP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ameriprise Finl analyst ratings.</a>
<h2>Unveiling the Story Behind Ameriprise Finl</h2>
Ameriprise Financial is a major player in the US market for asset and wealth management, with around $1.5 trillion in total assets under management and administration at the end of 2024. With about 10,500 advisors, Ameriprise has one of the largest branded advisor networks in the industry. About 80% of the company's revenue comes from its asset and wealth management segments. Ameriprise has reduced its exposure to insurance with the sale of its auto and home insurance business in 2019 and discontinuing the sale of proprietary fixed annuities in 2020.
<h3>Unraveling the Financial Story of Ameriprise Finl</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Ameriprise Finl's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.27%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Ameriprise Finl's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 13.39%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.94%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Ameriprise Finl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.32%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 1.14, Ameriprise Finl adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where Ameriprise Finl Stands With Analysts

Victory Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCTR#NASDAQ">VCTR</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $72.33, a high estimate of $87.00, and a low estimate of $59.00. A 0.92% drop is evident in the current average compared to the previous average price target of $73.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745964063_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Victory Capital Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$69.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Etienne Ricard</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Victory Capital Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Victory Capital Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Victory Capital Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Victory Capital Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VCTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Victory Capital Holdings analyst ratings.</a>
<h2>Get to Know Victory Capital Holdings Better</h2>
Victory Capital Holdings Inc is an independent investment management firm. The company operates its business through franchises and solutions platform. It provides centralized distribution, marketing, and operations infrastructure to the company's franchises and solutions platform. The company operates through one business segment that is Investment management services and products to institutional, intermediary, retirement platforms, and individual investors. The franchises and solutions platform manages a variety of investment strategies for its customers. It derives majority of its revenues from asset-based fees from investment management products and services to individuals and institutions.
<h3>Victory Capital Holdings: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Victory Capital Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 12.91%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Victory Capital Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 33.11%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Victory Capital Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 6.7%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Victory Capital Holdings's ROA excels beyond industry benchmarks, reaching 2.98%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.86, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VCTR

6 Analysts Assess Victory Capital Holdings: What You Need To Know

In the preceding three months, 4 analysts have released ratings for WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $106.0, with a high estimate of $115.00 and a low estimate of $100.00. This current average reflects an increase of 2.91% from the previous average price target of $103.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745964048_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive WEC Energy Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$101.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Neil Kalton</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$112.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to WEC Energy Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of WEC Energy Group compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of WEC Energy Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of WEC Energy Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WEC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WEC Energy Group analyst ratings.</a>
<h2>Delving into WEC Energy Group's Background</h2>
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 34% gas distribution, 10% electric transmission, and 7% unregulated renewable energy.
<h3>Financial Insights: WEC Energy Group</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, WEC Energy Group showcased positive performance, achieving a revenue growth rate of 3.01% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Utilities sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: WEC Energy Group's net margin excels beyond industry benchmarks, reaching 19.85%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): WEC Energy Group's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.71% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): WEC Energy Group's ROA stands out, surpassing industry averages. With an impressive ROA of 0.98%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: WEC Energy Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.64.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WEC Energy Group Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Throughout the last three months, 9 analysts have evaluated Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.44, a high estimate of $59.00, and a low estimate of $44.00. A 5.22% drop is evident in the current average compared to the previous average price target of $53.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1745964038_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Schlumberger. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Lemoine</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$58.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$59.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Schlumberger. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Schlumberger compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Schlumberger's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Schlumberger's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SLB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Schlumberger analyst ratings.</a>
<h2>Get to Know Schlumberger Better</h2>
SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts roughly $3 billion in digital-related revenue.
<h3>Unraveling the Financial Story of Schlumberger</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3M period, Schlumberger faced challenges, resulting in a decline of approximately -2.49% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Schlumberger's net margin is impressive, surpassing industry averages. With a net margin of 9.39%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.92%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.63%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.72, Schlumberger adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Schlumberger Through The Eyes Of 9 Analysts

4 analysts have expressed a variety of opinions on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $20.0, a high estimate of $26.00, and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.09%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745964024_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of WAVE Life Sciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Seedhouse</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Roger Song</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to WAVE Life Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of WAVE Life Sciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for WAVE Life Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into WAVE Life Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WVE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WAVE Life Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About WAVE Life Sciences</h2>
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
<h3>Breaking Down WAVE Life Sciences's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining WAVE Life Sciences's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 188.23% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: WAVE Life Sciences's net margin is impressive, surpassing industry averages. With a net margin of 34.93%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): WAVE Life Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): WAVE Life Sciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 8.23%, the company showcases efficient use of assets and strong financial health.
Debt Management: WAVE Life Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: WAVE Life Sciences In The Eyes Of 4 Experts

Health Care

Press Releases

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Clinical Trial Results Show Positive Signs For Potential New Dementia Treatment

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

General

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Agenus

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Biomea Fusion

Climb Bio

Caribou Biosciences

Elicio Therapeutics

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Seres Therapeutics

MediciNova

Sutro Biopharma

Instil Bio

Tenaya Therapeutics

Vigil Neuroscience

Vor Biopharma

XBiotech

Exicure

D. Boral Capital

Roth MKM

Canaccord Genuity

Chardan Capital

Jones Trading

Screenshot 2024-11-26 at 7.00.24 PM

Biotech

Interview

매일 거래일마다 벤징가 프로(Benzinga Pro)에서는 수백 개의 헤드라인과 보도자료가 제공된다. 여기에서 트레이더들은 전체 시장 및 <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0401" target="_blank" rel="noreferrer noopener">개별 주식에 대한 최신 뉴스를 확인할 수 있다.</a>
오늘은 3월에 벤징가 프로에서 가장 많이 검색된 주식을 살펴보려고 한다. 현재 주가 및 연초 대비 수익률은 4월 1일을 기준으로 하며 배당금은 포함되지 않는다.
1. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>현재 주가: $269.44</li>
<li>52주 범위: $138.80 ~ $488.54</li>
<li>연초 대비 수익률: -28.9%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 2위</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/03/44124338/exclusive-februarys-20-most-searched-tickers-on-benzinga-pro-where-do-tesla-palantir-alibaba-nvidia-rank">2025년 2월 벤징가 프로 검색 순위</a>: 5위</li>
</ul>
2. SPDR S&amp;P 500 ETF 신탁 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>현재 가격: $556.96</li>
<li>52주 범위: $493.86 ~ $613.23</li>
<li>연초 대비 수익률: -4.7%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 3위</li>
<li>2025년 2월 벤징가 프로 검색 순위: 3위</li>
</ul>
3. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>현재 주가: $108.05</li>
<li>52주 범위: $75.61 ~ $153.13</li>
<li>연초 대비 수익률: -21.9%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 1위</li>
<li>2025년 2월 벤징가 프로 검색 순위: 2위</li>
</ul>
4. 인베스코 QQQ 신탁 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>현재 가격: $468.31</li>
<li>52주 범위: $413.07 ~ $540.90</li>
<li>연초 대비 수익률: -8.3%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 8위</li>
<li>2025년 2월 벤징가 프로 검색 순위: 17위</li>
</ul>
5. 마이크로알고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>)
<ul>
<li>현재 주가: $22</li>
<li>52주 범위: $1.11 ~ $509.40</li>
<li>연초 대비 수익률: +517.9%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 상위 20위 미포함</li>
<li>2025년 2월 벤징가 프로 검색 순위: 상위 20위 미포함</li>
</ul>
6. 팔란티어 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)
<ul>
<li>현재 주가: $82.83</li>
<li>52주 범위: $20.33 ~ $125.41</li>
<li>연초 대비 수익률: +10.2%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 7위</li>
<li>2025년 2월 벤징가 프로 검색 순위: 4위</li>
</ul>
7. 비저너리 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>)
<ul>
<li>현재 주가: $3.19</li>
<li>52주 범위: $1 ~ $9.60</li>
<li>연초 대비 수익률: +30.7%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 상위 20위 미포함</li>
<li>2025년 2월 벤징가 프로 검색 순위: 상위 20위 미포함</li>
</ul>
8. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>현재 주가: $221.45</li>
<li>52주 범위: $164.08 ~ $260.09</li>
<li>연초 대비 수익률: -9.2%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 5위</li>
<li>2025년 2월 벤징가 프로 검색 순위: 16위</li>
</ul>
9. 슈퍼마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>현재 주가: $34.59</li>
<li>52주 범위: $17.25 ~ $106.90</li>
<li>연초 대비 수익률: +15.1%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 4위</li>
<li>2025년 2월 벤징가 프로 검색 순위: 1위</li>
</ul>
10. D-웨이브 퀀텀 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)
<ul>
<li>현재 주가: $7.37</li>
<li>52주 범위: 75센트 ~ $11.95</li>
<li>연초 대비 수익률: -11.67%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024년 벤징가 프로 검색 순위</a>: 상위 20위 미포함</li>
<li>2025년 2월 벤징가 프로 검색 순위: 상위 20위 미포함</li>
</ul>
다음 주식들은 2025년 2월에 가장 많이 검색된 주식 중 11위에서 20위까지의 목록이다.
<ul>
<li>11. 아마존 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>12. 인텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>13. 브로드컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</li>
<li>14. 세르보메드 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>)</li>
<li>15. 플러스 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>)</li>
<li>16. 스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)</li>
<li>17. 메타 플랫폼스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>18. 애클라리온 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>)</li>
<li>19. 마이크로소프트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>20. 앱러빈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)</li>
</ul>
왜 중요한가: 테슬라가 3월에 벤징가 프로에서 가장 많이 검색된 티커로 다시 올라서면서 SPDR S&amp;P 500 ETF 신탁을 근소하게 앞질렀다. 테슬라는 지난 2년간 많은 검색에서 1, 2위를 차지했으며 2024년에는 2월에 5위로 떨어지기 전까지 두 번째로 많이 검색된 티커로 2024년을 마감했다.
2월 17위에서 3월 4위로 상승한 인베스코 QQQ 트러스트는 3월에 가장 큰 폭으로 상승한 종목 중 하나였다. 애플도 16위에서 8위로 상위 10위권에 재진입했다.
2월에 1위를 차지했던 슈퍼 마이크로 컴퓨터는 3월에 9위로 떨어졌다. 이 회사는 최근 몇 달 동안 벤징가 프로에서 가장 많이 검색된 티커 중 하나다.
3월에 가장 많이 검색된 티커 목록은 2월에 가장 많이 검색된 20개 티커 목록에서 상위 10개 중 7개만 포함되는 등 크게 달라졌다. 이 7개 티커 중 5개는 2월과 3월 모두 상위 10위 안에 들었다.
3월에 새로 등장한 종목으로는 마이크로알고, 비저너리 홀딩스, D-웨이브 퀀텀이 있으며 이들 종목 모두 한 달 동안 주요 뉴스가 있었다.
마이크로 알고는 3월에<a href="https://www.benzinga.com/news/25/03/44463040/why-microalgo-mlgo-stock-is-skyrocketing"> 2천만 달러의 공모를 발표했다</a>. 비저너리 홀딩스는 카타르의 알파단 그룹과 <a href="https://www.benzinga.com/news/25/03/44168361/visionary-holdings-gv-stock-is-up-320-this-week-whats-going-on">10억 달러</a> 규모의 자금 조달 계약을 체결하여 새로운 에너지 차량의 R&amp;D 및 글로벌 확장을 지원한다고 <a href="https://www.benzinga.com/news/25/03/44168361/visionary-holdings-gv-stock-is-up-320-this-week-whats-going-on">발표했다</a>. D-웨이브는 전년 대비 502% 증가한 1,830만 달러의 <a href="https://www.benzinga.com/25/03/44333718/d-wave-quantum-stock-surges-following-strong-q4-bookings-growth-whats-going-on">4분기 예약을 기록했다</a>.
11위부터 20위까지는 2월에 가장 많이 검색된 상위 20위에 속했던 아마존, 인텔, 앱러빈이 포함되었다. 이 주식들은 3월에 각각 13위, 18위, 14위를 차지했다.
11위에서 20위 종목 10개 중 5개 종목이 2024년에 가장 많이 검색된 20개 티커에 포함되었으며, 아마존, 인텔, 스트레티지, 메타, 마이크로소프트가 모두 상위 20위 안에 들었다.
3월 목록에서 빠진 주식 중 하나는 AMD(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)로, 2월에 11위였으며 2024년에는 6번째로 많이 검색된 주식이었다.
사진: Insta_Photos via Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 주식은 미국 동부 시간 오후 2시에 혼조세를 보였으며, S&amp;P 500 지수는 화요일 약 0.1% 하락했다.
다우 지수는 0.02% 하락한 44,393.25로 거래되었고, 나스닥 지수는 0.03% 상승한 19,743.54로 거래되었다. S&amp;P 500 지수 또한 0.06% 하락하여 6,049.44로 거래되었다.
주요 섹터 동향
화요일에 통신 서비스 주식이 2.3% 상승했다.
반면, 화요일에는 부동산 주식이 1% 하락했다.
주요 뉴스
화요일에 오토존(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>)은 1분기 실적이 예상보다 저조하게 나타났다고 발표했다.
이 회사는 주당 순이익이 $32.52로, 시장 예상치인 $33.76을 하회했으며, 분기 매출이 $42억 8천만(+2.1% 전년 대비)으로 분석가 컨센서스인 $43억에 못 미쳤다.
주가 상승 종목
<ul>
<li>키메릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) 주식이 213% 급등하여 $2.71로 거래되었다. 이는 회사가 재발성 H3 K27M-변이 확산성 교모세포종 환자를 위한 도르다비프론(dordaviprone)의 가속 승인 신청을 제출할 것이라고 발표한 후 발생한 일이다.</li>
<li>또한, 컴벌랜드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) 주식이 94% 급등하여 $2.4001로 거래되었다. 이는 회사가 FDA로부터 아세타도트(acetadote)에 대한 보충 신약 신청이 승인되었다고 발표한 후 발생한 일이다.</li>
<li>유니큐어 N.V.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) 주식도 상승하였으며, 129% 상승하여 $16.71로 거래되었다. 이는 회사가 AMT-130에 대한 가속화 경로의 주요 요소에 대해 FDA와 합의했다고 발표한 후 발생한 일이다.</li>
</ul>
주가 하락 종목
<ul>
<li>서보메드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) 주식이 77% 하락하여 $2.34로 거래되었다. 이는 회사가 네플라마피모드(Neflamapimod)의 2b 단계 시험이 치매 치료를 위한 주요 목표를 달성하지 못했다고 발표한 후 발생한 일니다.</li>
<li>이엑스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) 주식이 17% 하락하여 $7.07로 거래되었다. 이는 회사가 3분기 실적을 발표한 후 발생한 일이다.</li>
<li>메디롬 헬스케어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) 주식이 46% 하락하여 $1.52로 거래되었다. 메디롬 헬스케어 테크놀로지스는 286만 개의 미국 예탁증서(ADS)에 대한 500만 달러 공모가를 주당 1.75달러에 책정했다.</li>
</ul>
원자재 상품 시장
상품 뉴스에 따르면, 원유 가격이 0.7% 상승하여 $68.84로 거래되었고, 금 가격이 1.2% 상승하여 $2,718.80로 거래되었다.
은 가격은 0.4% 상승하여 $32.73으로 거래되었고, 구리 가격은 0.1% 하락하여 $4.2730으로 거래되었다.
유로존
유럽 주식은 오늘 하락 마감했다. 유로존의 STOXX 600 지수가 0.52% 하락했으며, 독일의 DAX 지수가 0.08% 하락하고, 프랑스의 CAC 40 지수가 1.14% 하락했다. 스페인의 IBEX 35 지수는 0.38% 하락했으며, 런던의 FTSE 100 지수는 0.86% 하락했다.
아시아 태평양 시장
아시아 시장은 월요일에 혼조세로 마감되었다. 일본의 닛케이 225 지수는 0.18% 상승했고, 홍콩의 항셍 지수는 2.76% 상승했다. 중국의 상하이 종합 지수는 0.05% 하락했으며, 인도의 BSE 센섹스는 0.25% 하락했다.
경제 지표
미국 비농업 사업 부문 노동 생산성이 3분기에 2.2% 증가하여 예비치와 일치했다.
지금 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/24/12/42412458/amazon-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday">아마존이 약 15% 상승할까요? 화요일을 위한 10개의 주요 애널리스트 예측</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

CervoMed

뉴스

에 대한 최신 뉴스 CervoMed (NASDAQ:CRVO) 주식

수요일, 4월 02, 2025

화요일, 12월 10, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌